www.dailypolitical.com ·
inhibrx biosciences nasdaqinbx shares gap up heres why
Topic context
This topic has been covered 229632 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article reports a share price gap-up for Inhibrx Biosciences, a biotech firm developing protein therapeutics. The commercial mechanism is weak: no new clinical data, regulatory event, or partnership announced. The price move appears driven by analyst upgrades and market sentiment rather than a fundamental change in revenue or cost outlook. No direct impact on product prices, supply chains, or margins is evident.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Inhibrx Biosciences (NASDAQ:INBX) shares opened at $150.00 on May 13, 2026, up from $134.35 close.
- Trading volume of 476,211 shares.
- Analyst ratings: Stifel Nicolaus 'buy', Lifesci Capital 'strong-buy', consensus 'hold' with average price target $150.00.
- Reported quarterly loss of $2.11 per share, slightly missing consensus estimate.
- Lead candidate INBRX-109 aims at stimulating tissue repair.
